HPK1 as a novel target for cancer immunotherapy

Area of Science:

• Immunology
• Cancer Research
• Drug Discovery

Background:

• Developing novel anti-tumor immunotherapies faces significant risks in target identification.
• Hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase, is a potential therapeutic target.

Purpose of the Study:

• To investigate the role of HPK1 in T cell and dendritic cell function for anti-tumor immunotherapy.
• To evaluate the therapeutic potential of targeting HPK1 in a preclinical cancer model.

Main Methods:

• Genetic disruption of HPK1 in T cells and dendritic cells (DCs).
• Assessing T cell function (cytokine production, proliferation, suppression resistance).
• Evaluating anti-tumor efficacy via adoptive T cell transfer and DC-based cancer vaccines in mice.
• Assessing HPK1 expression in major organs.

Main Results:

• HPK1-deficient T cells exhibit enhanced Th1 cytokine production, proliferation, and resistance to PGE(2)-mediated suppression.
• Adoptive transfer of HPK1-deficient T cells conferred resistance to lung tumor growth in mice.
• HPK1-deficient DCs demonstrated superior antigen presentation, leading to a potent anti-tumor immune response.
• HPK1 is not significantly expressed in major organs, suggesting a favorable safety profile for inhibitors.

Conclusions:

• Targeting HPK1, particularly through kinase inhibition, holds promise for synergistic anti-tumor immunotherapy.
• HPK1 disruption enhances both T cell and dendritic cell-mediated anti-tumor immunity.
• The restricted expression of HPK1 suggests a low risk of systemic side effects from its inhibition.